Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems-Reference-Cited by-同舟云学术

Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems

Published:2020-09-01 Issue:6 Volume:48 Page:835-851
ISSN:0300-8126
Container-title:Infection
language:en
Short-container-title:Infection

Author:

Karakonstantis Stamatis^ORCID,Kritsotakis Evangelos I,Gikas Achilleas

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s15010-020-01520-6.pdf

Reference198 articles.

1. Papst L, Beović B, Pulcini C, Durante-Mangoni E, Rodríguez-Baño J, Kaye KS, et al. Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals. Clin Microbiol Infect. 2018;24:1070–6. https://doi.org/10.1016/j.cmi.2018.01.015.

2. Piperaki ET, Tzouvelekis LS, Miriagou V, Daikos GL. Carbapenem-resistant Acinetobacter baumannii: in pursuit of an effective treatment. Clin Microbiol Infect. 2019;25:951–7. https://doi.org/10.1016/j.cmi.2019.03.014.

3. Karakonstantis S, Kritsotakis EI, Gikas A. Pandrug-resistant Gram-negative bacteria: a systematic review of current epidemiology, prognosis and treatment options. J Antimicrob Chemother. 2019;75:271–82. https://doi.org/10.1093/jac/dkz401.

4. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: no ESKAPE! An update from the infectious diseases society of America. Clin Infect Dis. 2009;48:1–12. https://doi.org/10.1086/595011.

5. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18:318–27. https://doi.org/10.1016/S1473-3099(17)30753-3.

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Limited Impact of Colistin Resistance on Mortality of Intensive Care Patients with Carbapenem-resistant Bacteraemia;Journal of Hospital Infection;2024-08

2. Treatment of infections caused by carbapenem-resistant Acinetobacter baumannii;Frontiers in Cellular and Infection Microbiology;2024-07-18

3. Profile characteristics of sensitivity to antimicrobial chemotherapeutic drugs of Corynebacterium jeikeium isolated in explosive mine injuries of the limbs;The Journal of V. N. Karazin Kharkiv National University, Series "Medicine";2024-06-28

4. AI‐driven drug discovery: Exploring Abaucin as a promising treatment against multidrug‐resistant Acinetobacter baumannii;Health Science Reports;2024-06

5. Outcomes of 23 patients diagnosed with New Delhi metallo-beta-lactamase (NDM)-producing Klebsiella pneumoniae infection treated with ceftazidime/avibactam and aztreonam at a single center in Poland;European Journal of Clinical Microbiology & Infectious Diseases;2024-05-29